|
Driven by increasing affordability, shifting disease
pattern and modest healthcare and services in the country growing at a
compounded annual rate of 14% from 2000-2005, the Pharmaceutical industry
accounts for 15-20% of the total healthcare spent, growing at a compound
rate of 9%.
Analysis shows that if the Indian economy continues on
its high current growth path, the Indian Pharmaceutical market will
undergo a major transformation in the next decade. The market will triple
to USD 20 billion by 2015 and move into the world’s ten top
Pharmaceutical market compounding to an annual growth rate of 12.3 %.
India along with Japan, Canada and UK will move to the next level with
USA and Chine with a growth expectation of USD 20-23 billion by 2015.
Looking at the above scenario, Indian Pharmaceutical
industry will require a large group of highly trained professionals to
bring about a change required for achieving such high goal. Hence it is
imperative that to attain the projected business volumes, India needs to
invest heavily in two segments i.e.,
·
Infrastructure in high end manufacturing and
testing facility
·
Focused training as per international standards
for effective global presence.
CII’s vision for 2020 is not only to position India in
the first 5 countries in the global Pharma and Biotech sector
contributing 20% of the economic growth, but also to showcase its national
Pharma/Biotech industry for enhancement of knowledge and skills at the
international level. Consequently, CII_IQ has drawn up an ambitious road
map to transcend business driven research-to-research driven
business. The immediate milestone to be crossed is that of
focused and tailor made training programmes for the Pharma/Biotech
industry within India for enhancement of knowledge and skills to
international level.
Deliverable
Consequently, CII_IQ has entered into a MOU with Mandava
Associates of USA to provide consultancy and organize high-end training
in different areas if Pharma and Biotechnology. Mandava Associates has
over 100 years combined experience in product development, product
approval and regulatory services and has in-depth knowledge in the areas
of Pharmaceutical, Biotechnology, Biologics and medical devices. The
organization has a successful track record of handling applications and
submissions for marketing and authorization to regulatory authorities worldwide.
Future Plans
CII_IQ is also planning to work closely with
Confederation of Indian Pharma Industry (CIPI) to promote basic training
programmes for SME sectors in different Pharma/Biotech clusters in India.
To begin with, CII_IQ has conducted in-house training programmes in the
area of cGMP, international cGMP, computer validation, Pharmaco vigilance
and Epidemology and advances
in Clinical Trials with Jubilant Organosys, Shashun, Lotus, Dabur,
Reddy’s Labaoratories and Lamda Therapeutics.
CII-IQ has already chalked plans to conduct 8 in-house
training programmes in Good Pharma Practices (GPP), 6 programmes on
Quality Assurance and Audit (QAA) and 4 inhouse programmes on Pharma
Resource Building (PRB) during 2008-2009 for high end Pharma and Biotech
Industry. It is also planning to conduct 12 open house programmes for the
SME clusters in association with CIPI out of which 6 programmes will be
supported by Quality Council of India.
|
